



Anti-Angiogenesis Therapeutics in Cancer

Guest Editor:

Prof. Dr. Shaker A. Mousa

1. Retired, The Pharmaceutical
Research Institute, Albany
College of Pharmacy and Health
Sciences, 1 Discovery Drive
(Room 238), Rensselaer, NY
12144, USA

2. Vascular Vision
Pharmaceuticals Co., Rensselaer
Polytechnic Park, Troy, NY 12180,
USA

Deadline for manuscript
submissions:

closed (30 March 2017)

Message from the Guest Editor

Dear Colleague,

The aim of this Special Issue is to cover the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in Oncology. The Special Issue is aimed to cover preclinical and clinical steps involved in the discovery and development of anti-angiogenesis targets in cancer and to discuss mechanisms involved in the modulation of angiogenesis in relation to cancer therapy. FDA approved anti-angiogenesis agents in cancer therapeutics and limitations will be reviewed. Furthermore, the implications of Nanotechnology in expanding the utility of existing and new novel anti-angiogenesis strategies in cancer will also be reviewed.

Prof. Dr. Shaker A. Mousa

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)